NCT03110315View on ClinicalTrials.gov

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Multiple SclerosisFatigueInsomnia
Interventions
DRUG

Suvorexant

See detailed information in associated Arm Description.

DRUG

Placebo

Sugar pill manufactured to mimic suvorexant 10 mg tablet.

Trial Locations (1)

98034

EvergreenHealth Multiple Sclerosis Center, Kirkland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Theodore R. Brown, MD MPH

OTHER

NCT03110315 - A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia | Biotech Hunter | Biotech Hunter